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Abstract The second FMRFamide-gated Na+ channel (HtFa-
NaC), from Helisoma trivolvis, has been cloned. HtFaNaC has
some different pharmacological properties to HaFaNaC, from
Helix aspersa, which has enabled a rational approach to be made
to start to identify the FMRFamide recognition site. Several
chimeras were made by switching sections between the channels.
The differences in sensitivity to FMRFamide, and amiloride,
were assessed after expression in Xenopus oocytes. The data
suggest that a recognition site for FMRFamide, and the
potentiating action of amiloride, resides in a sequence of about
120 amino acids in the extracellular loop proximal to the first
transmembrane segment. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The only known peptide-gated ion channels are the
FMRFamide (Phe-Met-Arg-Phe-NH2)-gated Na channels
(FaNaCs) of snail neurons [1^3]. They are members of a class
of channels typi¢ed by the epithelial amiloride-sensitive Na
channels or ENaCs [4^6]. Members of this family of channels
appear to be abundant in di¡erent species. For example, 24
amiloride-sensitive Na channels are predicted from analysis
of the Drosophila genome, and 22 in Caenorhabditis [7] ; sev-
eral neuronal members of the family have been identi¢ed in
mammals [8^10]. Available evidence suggests that subunits of
all these channels possess only two transmembrane domains
(TMs) and an extracellular loop that incorporates several cys-
teines. In the case of the FaNaCs, the extracellular loop com-
prises about 450 amino acids; the heterologously expressed
channels are probably homotetramers [11].
The ENaCs are constitutively active. On the other hand, the
FaNaCs require activation, as do other neuronal members of
this family identi¢ed in vertebrate and invertebrate species.
The natural ligand for the FaNaCs (FMRFamide) is known,
but the natural means of activation of the other related neuro-
nal channels are controversial ; some may be mechanosensors
[12,13], while others can be activated by acid pH [8,10]. There
is considerable interest in identifying the physiological roles of
these channels. It is possible that some are activated by precise
sequences of amino acids that are either incorporated into
speci¢c proteins or free as peptides, yet to be de¢ned. Little
is known about the receptive sites of these channel proteins.
Two FaNaCs have been cloned. Although the proteins
share 65% identity and highly conserved regions within the
extracellular loop, they exhibit di¡erent sensitivities to
FMRFamide and amiloride-like drugs. When expressed in
Xenopus oocytes, HaFaNaC (from Helix aspersa) has an
EC50 of 2 WM for FMRFamide and is blocked by amiloride
[2], but HtFaNaC (from Helisoma trivolvis) has an EC50 of 70
WM for FMRFamide and is potentiated by amiloride [3].
These two channels therefore provide a good model for inves-
tigating the interaction of an amiloride-sensitive Na channel
with its native ligand as well as with amiloride.
Here we report a series of experiments in which several
chimeric channels have been made by switching sequences
between conserved regions of HaFaNaC and HtFaNaC and
then studied electrophysiologically after expression in Xenopus
oocytes. The results suggest that the receptive site for
FMRFamide, and also the site responsible for amiloride po-
tentiation, reside much closer to TM1 than to TM2.
2. Materials and methods
A diagrammatic representation of the predicted primary structure
of the FaNaCs and the chimeras made is shown in Fig. 1. Both
HaFaNaC and HtFaNaC are cloned into the pXENEX1 vector opti-
mized for Xenopus oocyte expression [3]. Master chimeric constructs
were created as follows: each cDNA possesses a unique PpuMI site at
an identical location in the fully conserved region prior to TM2. A
unique NdeI restriction site was introduced into a highly conserved
domain just prior to the TM1 region in each cDNA by creating a
silent mutation with the Stratagene QuikChange kit. The ¢delity of
these and all ensuing constructs was con¢rmed by dideoxy sequencing.
The entire extracellular loop region of each channel cDNA was then
ampli¢ed using the Expand High Fidelity polymerase chain reaction
(PCR) system kit (Boehringer Mannheim); the PCR primers were also
designed to change the single non-conserved residue within TM1 of
each channel (I79 in HtFaNaC, A76 in HaFaNaC) to that of the
counterpart channel, which ensured that the sequence of TM1 was
consistent with that of the N-terminus. Each ampli¢ed product was
cut with NdeI and PpuMI and ligated into the similarly digested
plasmid for the other channel. The resulting chimeras comprised ei-
ther the Helisoma (Ht) intracellular termini and TMs and the Helix
(Ha) sequence of the extracellular loop (labeled Ht(Ha89^536)Ht or
tat1; see Fig. 1B), or the Helix termini and TMs and the Helisoma
extracellular loop (Ha(Ht92^534)Ha or ata1). Each construct is iden-
ti¢ed by the portion of the extracellular domain from one channel
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(numbered positions in the peptide sequence) that has replaced the
corresponding region in the counterpart channel; see Fig. 1A for a
full alignment of the two channel sequences. Subsequent chimeras
incorporating smaller regions of the extracellular domain were created
from the wild-type channels and/or previously made chimeras using
the ‘gene splicing by overlapping extension’ PCR protocol [14]. All
splice sites are embedded within highly conserved regions (see Fig. 1).
A point mutation was generated using the Stratagene kit to correct a
PCR-induced error in one construct.
cDNAs of HaFaNaC and HtFaNaC and the di¡erent chimeras
were linearized and transcribed using the T7 version of the mMessage
mMachine in vitro transcription kit (Ambion). Samples of cRNAs
were denatured, electrophoresed on denaturing formaldehyde gels,
and stained with SYBR Green (Molecular Probes) to determine con-
centration and purity. Oocytes were removed from Xenopus under
MS-222 anesthesia and treated with 2 mg ml31 collagenase (Sigma
Type II or Type I) to remove the follicular cell layer. 0.5^5 ng of
cRNA was injected into each oocyte. Oocytes were stored at 18‡C
in ND96 containing 5% horse, or fetal calf, serum, 2.5 mM Na py-
ruvate, 100 U ml31 penicillin and 100 Wg ml31 streptomycin (Sigma).
The sensitivity to FMRFamide (Sigma) and response to amiloride
(Sigma) were assessed electrophysiologically with two electrode volt-
age-clamp 2^10 days after injection.
The voltage-clamp experiments were made with oocytes placed in a
0.5 ml bath that allowed continuous exchange of the physiological
solution (ND96). Low resistance (6 1 M6) micro-electrodes ¢lled
with 3 M KCl were used. Flow through the bath was about 5 ml
min31. Test solutions were applied in 1 ml samples and allowed to
£ow through the bath at the same rate. The e¡ect of amiloride was
tested by adding 5^6 ml of a 100 WM solution in ND96 immediately
before the peptide dilution. ND96 solution contained: (in mM) NaCl
96, KCl 2, CaCl2 1.8, MgCl2 1, HEPES 5, adjusted to pH 7.4 with
NaOH.
3. Results
The chimera comprising the intracellular tails and TMs of
HtFaNaC with the extracellular loop of HaFaNaC, i.e.
Ht(Ha89^536)Ht or tat1, had an EC50 for FMRFamide of
5 WM and was blocked by amiloride (Figs. 2 and 3). Record-
ings made under identical conditions with HaFaNaC gave a
FMRFamide EC50 value of 3 WM and amiloride block. In
contrast, the FMRFamide EC50 was 300 WM for the construct
Ha(Ht92^534)Ha or ata1, and amiloride potentiated the
FMRFamide response (Figs. 2 and 3). Under the same con-
ditions the FMRFamide EC50 was 70 WM for HtFaNaC and
amiloride potentiated the peptide response. These experiments
con¢rmed that the approach was generally sound in that the
responses of chimeras were similar to those of the channels
from which the extracellular loop was taken.
Portions of the extracellular domain preceding TM2 of the
Fig. 1. A: Alignment of the peptide sequences of the FaNaCs from H. trivolvis (Ht) and H. aspersa (Ha). The locations of the splice sites used
in constructing the chimeras are marked by vertical lines, followed by the numerical positions of the succeeding residues. Conserved cysteines
are marked by asterisks, and the proposed locations of the two TM segments are indicated by shading. B: Diagrammatic representation of the
two wild-type channels and the chimeras constructed and studied in the present experiments. Each chimera is represented by mixtures of black
(portions of HaFaNaC) and white (portions of HtFaNaC). A summary of the pharmacological responses of each construction is shown to the
right; see Fig. 2 for a more detailed illustration of the FMRFamide responses.
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construct Ht(Ha89^536)Ht, or tat1, were then replaced with
the corresponding HtFaNaC segments. These new chimeras
were Ht(Ha89^427)Ht, or tat2, and Ht(Ha89^325)Ht, or tat3.
The sections switched included a domain that occurs only in
the FaNaCs and di¡ers markedly in amino acid sequence
between the two channels (see Fig. 1). The expectation was
that the responses of such constructs would mimic those of
HtFaNaC. However, both tat2 and tat3 exhibited properties
that were very similar to those of HaFaNaC and tat1; the
FMRFamide EC50 values were about 10 WM and 7 WM for
tat2 and tat3, respectively, and the FMRFamide current was
blocked with amiloride in each case (Figs. 2 and 3). Similarly,
another chimera comprising mainly HaFaNaC with a short
section preceding TM2 from HtFaNaC, i.e. Ha(Ht430^
534)Ha or ata5, responded to FMRFamide with an EC50 of
3 WM with amiloride blockade (Figs. 2 and 3). All these data
indicate that the di¡erences in pharmacology between HaFa-
NaC and HtFaNaC cannot be explained by di¡erences in the
sequences within the C-terminal section of the extracellular
loop. Rather, they suggest that the N-terminal portion is im-
portant.
Data from other HaHtHa chimeras provided further evi-
dence for this view. Three constructs were tested: Ha(Ht92^
332)Ha or ata2, Ha(Ht215^332)Ha or ata4, and Ha(Ht92^
214)Ha or ata3. The pharmacology of ata2, which essentially
has only the N-terminal half of the extracellular loop of
HtFaNaC inserted into HaFaNaC, was very similar to that
of the chimera comprising the entire extracellular loop of
HtFaNaC inserted into HaFaNaC, i.e. ata1.
A comparison of ata4 and ata3, on the other hand, showed
marked di¡erences in FMRFamide sensitivity and the e¡ect
of amiloride. Whereas the response of ata4 was very similar to
those of HaFaNaC and chimeras tat1, tat2, and tat3, with a
FMRFamide EC50 of about 10 WM and amiloride blockade,
the response of ata3 to FMRFamide was very weak, with an
EC50 close to 300 WM, and amiloride potentiated the response
(Figs. 2 and 3).
4. Discussion
The results show that switching sections of the extracellular
loop close to the N-terminal transmembrane region (TM1) of
the FMRFamide-gated channel had a profound e¡ect on the
FMRFamide EC50 values and the response to amiloride,
whereas changes in the extracellular loop close to the C-ter-
minal had little or no e¡ect.
Fig. 2. Examples of FMRFamide responses and the di¡erent e¡ects
of 100 WM amiloride. The upper recording of each pair shows the
response to FMRFamide alone and the lower recording the re-
sponse of the same concentration of FMRFamide with 100 WM
amiloride. In every case the e¡ect of amiloride was reversed with
washing (not shown). Application of FMRFamide is indicated by
the bar above each pair of recordings. The concentrations of
FMRFamide were: 1 WM for tat1 and ata4, 3 WM for HaFaNaC
and tat3, 10 WM for HtFaNaC and 100 WM for ata1 and ata3. As
with HaFaNaC, the e¡ect of amiloride on the tat chimeras was to
reduce the response to FMRFamide, whereas with HtFaNaC, ata1,
and ata3 (and ata2, not shown), amiloride enhanced the response to
FMRFamide. Inclusion of the extracellular Helix sequence adjacent
to TM1 abolished the enhancing e¡ect of amiloride on the FMRF-
amide response.
Fig. 3. Dose^response relationships of the di¡erent chimeras to FMRFamide. Data are shown as the mean þ S.E.M. of 3^5 experiments.
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EC50 values depend upon the a⁄nity of a ligand for its
receptor and also the degree to which the ligand alters the
conformational state of the receptor (gating or e⁄cacy) once
bound [15]. Thus, changes in EC50 values may re£ect a change
in a⁄nity alone, a change in gating alone, or a combination of
both. The FMRFamide EC50 value and amiloride sensitivity
of the chimeras tat3 and tat2 were very similar to tat1 (and
HaFaNaC), indicating that the changed sequences did not
in£uence either parameter, unless a change in one was pre-
cisely counteracted by a change in the other. In view of the
signi¢cant changes in sequence made (see Fig. 1A), it is most
likely that this region is not an important site for FMRF-
amide recognition. Comparison of the responses of ata5
with HaFaNaC also indicates that the C-terminal region of
the extracellular loop is not important for FMRFamide rec-
ognition. All these data imply that the FMRFamide recogni-
tion site(s) resides closer to TM1 than to TM2.
The chimeras ata2 and ata3 had similar EC50 values and
amiloride sensitivity to ata1 and HtFaNaC. ata4, on the other
hand, had a FMRFamide EC50 value very similar to HaFa-
NaC and was blocked by amiloride. Comparison of the re-
sponses of ata4, FMRFamide EC50 of 10 mM, and ata3,
FMRFamide EC50 of about 300 mM (see Fig. 2), suggests
that the sequence adjacent to TM1 is particularly important
in in£uencing whether the response is similar to HtFaNaC or
to HaFaNaC. Our conclusion is that this section, comprising
about 120 amino acids of the extracellular loop proximal to
TM1, is likely to be an important component of the FMRF-
amide recognition site. This region also appears to have a
major in£uence on channel gating, which is particularly ob-
vious with the marked enhancing e¡ect of amiloride on the
chimeras containing sections of sequence originating from
HtFaNaC. Single channel studies on HtFaNaC suggest that
amiloride and related drugs in£uence channel gating (see [3]).
An additional e¡ect of amiloride on FMRFamide binding has
not been ruled out.
The conclusion that FMRFamide binding is likely to occur
close to TM1 is relevant to other members of the family of
channels typi¢ed by the ENaCs. Although the FaNaCs di¡er
markedly in the C-terminus of the extracellular domain com-
pared to other members, the N-terminal region is similar in
size among the various members, albeit the level of conserva-
tion is relatively low. FMRFamide and some related peptides
have recently been shown to potentiate acid-gated currents in
rat dorsal root ganglion neurons, as well as heterologously
expressed acid-sensing ion channel (ASIC) K (ASIC1), ASICL,
and DRASIC (ASIC3) channels, an action that appears to be
exerted by FMRFamide binding directly to the channel [16].
Based on the contrasting e¡ects of FMRFamide on the
ASICK and ASICL splice variants, which di¡er in their N-
termini for approximately 180 residues, the ligand has been
proposed to bind within the N-terminal domain. A similar
location is supported by our ¢ndings; in fact, the C-termini
of the splice sites in the ASIC variants and the ata3 chimera
di¡er by only 11 residues.
TM2 and the adjacent extracellular region of ENaCs have
been strongly implicated in the formation of the pore and the
binding of amiloride, but regions near TM1 also play a role in
channel function. Coscoy et al. [17] have obtained evidence
that the pre-TM1 region in the ASICs participates in the
channel pore, and data of Grunder et al. [18] implicate a
region of TM1 of KENaC in channel gating. Our data further
demonstrate that the extracellular region adjacent to TM1 in
FaNaCs probably plays a role in ligand binding and channel
gating. It is noteworthy that the sequence with the highest
level of conservation at the nucleotide level (86%) between
HaFaNaC and HtFaNaC occurs in the region, corresponding
to about 70 amino acids, that forms part of the intracellular
N-terminal region, TM1, and a section of the extracellular
loop. The domain we have identi¢ed in the extracellular
loop is 69% identical in peptide sequence between the two
channels, and 56% identical in the portion bounded by the
¢rst and second conserved cysteines, but is poorly conserved
with respect to other members of the amiloride-sensitive Na
channel superfamily.
The region that appears to be important in the binding of
FMRFamide also helps to determine the action of amiloride.
The responses demonstrate that not only can amiloride block
be conferred upon chimeras comprising mainly HtFaNaC, but
also that an altered form of HaFaNaC can be potentiated by
amiloride, supporting our hypothesis of two interaction sites
for amiloride with FaNaCs [3,19]. Two distinct amiloride
binding sites have also been described in the mammalian
BNC1 (MDEG, ASIC2) channel [20], and may exist in other
ENaCs. Our data indicate that the response of such channels
to amiloride may be modulated by variations in the N-termi-
nus of the extracellular loop.
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